{"abstract": "The bid by Lilly for the biotechnology company beat out an offer from Bristol-Myers Squibb, which markets ImClone\u2019s cancer drug Erbitux in the United States along with ImClone.", "web_url": "https://www.nytimes.com/2008/10/07/business/07drug.html", "snippet": "The bid by Lilly for the biotechnology company beat out an offer from Bristol-Myers Squibb, which markets ImClone\u2019s cancer drug Erbitux in the United States along with ImClone.", "lead_paragraph": "Eli Lilly agreed on Monday to pay $6.5 billion to acquire ImClone Systems, the biotechnology company that is controlled by Carl C. Icahn and whose stock was involved in the insider trading scandal that sent Martha Stewart to jail. ", "source": "The New York Times", "multimedia": [], "headline": {"main": "Lilly to Buy ImClone for $6.5 Billion", "kicker": null, "content_kicker": null, "print_headline": "Eli Lilly to Buy ImClone for $6.5 Billion", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Lilly, Eli, & Co", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Bristol-Myers Squibb Co", "rank": 3, "major": "N"}, {"name": "organizations", "value": "ImClone Systems Incorporated", "rank": 4, "major": "N"}], "pub_date": "2008-10-06T12:20:53+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/374dad52-5ae0-565a-8abf-ed285b63546d", "word_count": 739, "uri": "nyt://article/374dad52-5ae0-565a-8abf-ed285b63546d"}